Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-ECG: Dapagliflozin Effects on Ventricular Repolarization in T2D
NCT06721442Phase 4Completed
- Sponsor
- BP - A Beneficência Portuguesa de São Paulo
- Start
- Jan 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by BP - A Beneficência Portuguesa de São Paulo. Primary endpoint: T-peak to T-end Interval at 90 days. Started Jan 2023; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06721442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06721442.